Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06672016 | Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential | PHASE3 | ACTIVE NOT_RECRUITING | 1,630 | — | — | Jan 13, 2025 | May 1, 2027 | May 6, 2026 | 56 | United States |
The primary efficacy endpoint will be pregnancy rate described by Pearl Index (PI). PI is defined as the number of pregnancies per 100 women-years.
| Arm | Type | Description |
|---|---|---|
| This is a single-arm study. | EXPERIMENTAL | The study patch is a transdermal system that contains the active ingredient progestin. This study is an open-label, single-arm study. This means that all participants in the study will receive the study patch |
| Name | Type | Description |
|---|---|---|
| Transdermal system containing progestin | DRUG | MR-130A-01 transdermal system, patch to be used for female contraception |
Inclusion Criteria: 1. Healthy, post-menarcheal and premenopausal women at risk of pregnancy who are at least 16 years of age. 2. Desires to avoid pregnancy, is seeking to use hormonal contraception for at least 1 year. 3. Has negative UPT results at screening and at enrollment visits. 4. Has norma...